Harvard Medical School, Boston, Massachusetts.
Department of Health Policy, Vanderbilt University School of Medicine, Nashville, Tennessee.
JAMA. 2019 Jul 16;322(3):267-269. doi: 10.1001/jama.2019.7521.
This study characterizes price increases exceeding inflation between 2012 and 2017 for protected-class drugs (antineoplastics, antiretrovirals, antidepressants, antipsychotics, anticonvulsants, and immunosuppressants for transplant patients) that would lead to their exclusion from Medicare Part D coverage based on excessive cost under a 2018 CMS rule intended to facilitate more effective price negotiations.
本研究描述了 2012 年至 2017 年期间受保护类药物（抗肿瘤药、抗逆转录病毒药、抗抑郁药、抗精神病药、抗惊厥药和移植患者用免疫抑制剂）的价格涨幅超过通胀率的情况，如果根据旨在促进更有效价格谈判的 2018 年 CMS 规则，这些药物的成本过高，则会将这些药物排除在医疗保险 Part D 覆盖范围之外。
